Phase 2 ProHear Study Reaches 50% Patient Enrollment
Acousia Therapeutics' ProHear Study is evaluating ACOU085 for the prevention of cisplatin-induced hearing loss in patients with testicular cancer undergoing chemotherapy.
Acousia Therapeutics' ProHear Study is evaluating ACOU085 for the prevention of cisplatin-induced hearing loss in patients with testicular cancer undergoing chemotherapy.